Annals of Surgical Oncology

, Volume 15, Issue 10, pp 2981–2982 | Cite as

Targeting VEGF, EGFR, and Other Interacting Pathways for Gastric Cancer—Promises and Reality

  • T. Liakakos
  • E. Fatourou
  • D. Ziogas
  • E. Lykoudis
  • Dimitrios H. Roukos
Gastrointestinal Oncology


Gastric Cancer Bevacizumab Capecitabine Adjuvant Setting Metastatic Gastric Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3:24–40.PubMedCrossRefGoogle Scholar
  3. 3.
    Schneider BP, Sledge GW Jr. Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 2007; 4:181–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666–76.PubMedCrossRefGoogle Scholar
  5. 5.
    Cunningham D, Chua YJ. East meets west in the treatment of gastric cancer. N Engl J Med 2007; 357:1863–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 2008; 8:29–39.PubMedCrossRefGoogle Scholar
  7. 7.
    Liakakos T, Roukos DH. More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 2008 Jan 23; [Epub ahead of print]. doi: 10.1245/s10434-007-9798-5
  8. 8.
    Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007; 6:308–12.PubMedCrossRefGoogle Scholar
  9. 9.
    Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2008; 358:197.PubMedCrossRefGoogle Scholar
  10. 10.
    Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007; 4:578–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Lieto E, Ferraraccio F, Orditura M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008; 15:69–79.PubMedCrossRefGoogle Scholar
  12. 12.
    Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005; 2:98–107.PubMedCrossRefGoogle Scholar
  13. 13.
    Roukos DH, Hottenrott C, Encke A, et al. Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 1994; 3:115–25.PubMedCrossRefGoogle Scholar
  14. 14.
    Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 2004; 11:127–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002; 81:59–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States?. Ann Surg Oncol 2004; 11:727–30.PubMedCrossRefGoogle Scholar
  17. 17.
    Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 1998; 80:16–24.PubMedGoogle Scholar
  18. 18.
    Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002; 9:220–1.PubMedCrossRefGoogle Scholar
  19. 19.
    Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007; 14:2691–5.PubMedGoogle Scholar
  20. 20.
    Briasoulis E, Liakakos T, Dova L, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6:931–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357:1810–2.PubMedCrossRefGoogle Scholar
  22. 22.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11–20.PubMedCrossRefGoogle Scholar
  23. 23.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725–30.PubMedCrossRefGoogle Scholar
  24. 24.
    Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007; 245:873–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Chung DC, Yoon SS, Lauwers GY, et al. Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer. N Engl J Med 2007; 357:283–91.PubMedCrossRefGoogle Scholar
  26. 26.
    Roukos DH. Linking contralateral breast cancer with genetics (editorial). Radiother Oncol 2008; 86:139–41Google Scholar
  27. 27.
    Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357:1555–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 2008; 15:21–33.PubMedCrossRefGoogle Scholar
  29. 29.
    Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002; 9:607–9.PubMedGoogle Scholar
  30. 30.
    Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002; 9:941–3.PubMedGoogle Scholar
  31. 31.
    Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004; 11:1030–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003; 10:718–21.PubMedCrossRefGoogle Scholar
  33. 33.
    Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005; 5:737–45.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  • T. Liakakos
    • 1
  • E. Fatourou
    • 1
  • D. Ziogas
    • 2
  • E. Lykoudis
    • 2
  • Dimitrios H. Roukos
    • 2
  1. 1.Athens UniversityAthensGreece
  2. 2.Ioannina University School of MedicineIoanninaGreece

Personalised recommendations